Last reviewed · How we verify
NCT06187311: REVISE-AF
Clinical Trial to Evaluate Efficacy and Safety of Rivaroxaban 15mg and 20mg in Patients With Non-valvular Atrial Fibrillation
Phase 4 trial testing Rivaroxaban 20 MG in Atrial Fibrillation in 940 participants. Currently enrolling.
30 June 2026
Quick facts
| Lead sponsor | Korea University Anam Hospital |
|---|---|
| Phase | Phase 4 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 940 |
| Start date | 12 January 2023 |
| Primary completion | 30 June 2026 |
| Estimated completion | 30 June 2027 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- Rivaroxaban 20 MG — full drug profile →
- Rivaroxaban 15 MG
Conditions studied
- Atrial Fibrillation — all drugs for Atrial Fibrillation →
- Anticoagulant Adverse Reaction — all drugs for Anticoagulant Adverse Reaction →
Sponsor
Korea University Anam Hospital
Who can join
Adults 19 to 99, any sex, with Atrial Fibrillation or Anticoagulant Adverse Reaction. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In this clinical trial, Rivaroxaban of standard dose (20mg) and reduced dose (15mg) will be administeted in non-valvular atrial fibrillation patients without severe renal dysfunction. It is a randomized, open-label, and phase 4 clinical trial to compare and evaluate efficacy and safety of Rivaroxaban. After obtaining informed consent to participate in this trial, screening is performed (Screening visit). Screening includes baseline 12-lead electrocardiography and laboratory tests to exclude severe end-organ dysfunction (such as renal dysfunction, liver dysfunction, or anemia). Baseline visits are available on the same day. After screening, subjects eligible for the trial will be randomly assigned (1:1 ratio) to Group 1 (15 mg of Rivaroxaban) or Group 2 (20 mg of Rivaroxaban) (Baseline visit). The study drug (Rivaroxaban 15mg or 20mg daily) will be administered for 12 months. During study period, a total of six visits (3,6,9,12 months) will be made, and follow-up test and outcome measurement will be done in each visit.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06187311
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Rivaroxaban 20 MG
Trials testing the same drug.
- NCT04477837 — Prospective Comparison of Incidence of Heavy Menstrual Bleeding in Women Treated With Direct Oral Anticoagulants · completed
- NCT03926780 — Comparative Study of Oral Anticoagulation in Left Ventricular Thrombi · Phase 3 · completed
- NCT03083704 — A Healthy Volunteer PK/PD, Safety and Tolerability Study of Second Generation Andexanet Alfa · Phase 1 · completed
- NCT03282643 — Rivaroxaban Versus Low-molecular-weight Heparin for Preventing Thrombosis in Cancer Patients · Phase 1, PHASE2 · completed
Other recruiting trials for Atrial Fibrillation
Currently open trials in the same condition.
- NCT07429214 — A Study of VARIPULSE Catheter and TRUPULSE Generator With VARIPULSE Pro Software in Participants With PAF or PsAF · NA · recruiting
- NCT07271238 — Feasibility Study on the VERAFEYE Imaging and Navigation System for Guided Catheter Ablation Procedures · NA · recruiting
- NCT07388108 — Atrial Dyssynchrony to Predict Arrhythmias in the Postoperative Setting of Cardiovascular Surgery. · recruiting
- NCT07428967 — AV Node Ablation and CONDUCTion System Pacing for Atrial Fibrillation With Preserved Left Ventricular Function · NA · recruiting
- NCT06650995 — AlEX-DHF: Ablation and Exercise in Diastolic Heart Failure · NA · recruiting
Other Korea University Anam Hospital trials
Trials by the same sponsor.
- NCT07510932 — Fruquintinib In Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies in South Korea Patients · Phase 2 · not yet recruiting
- NCT07280780 — CGM-Based Glycemic Analysis After ESI · not yet recruiting
- NCT07189000 — Patient-centered REhabilitation Program to Advance REcovery · NA · not yet recruiting
- NCT07246148 — NOn-inVAsive Blood Pressure Monitoring in Intracranial Aneurysm Embolization · NA · recruiting
- NCT07376980 — The SMART Trial: Modified Single-Stapled Anastomosis in Laparoscopic or Robotic Low Anterior Resection for Rectal Cancer · NA · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06187311 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Korea University Anam Hospital
- Last refreshed: 5 January 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06187311.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing